Journal Article

Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis

Reischl, Stephanie, Boerstler, Tom, Winner, Beate, Boldt, Karsten, Ravits, John, Wang, Ruth, Wheeler, Emily C, Wend, Holger, Yeo, Gene W, Aigner, Stefan, Regensburger, Martin, Krach, Florian, Winkler, Juergen, Vu, Anthony Q, Batra, Ranjan

2022

Overview

Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by aberrant alternative splicing (AS). Nuclear loss and cytoplasmic accumulation of the splicing factor TDP-43 in motor neurons (MN) are hallmarks of ALS at late stages of the disease. However, it is unknown if altered AS is present before TDP-43 pathology occurs. Here, we investigate altered AS and its origins in early stages of ALS using human induced pluripotent stem cell-derived motor neurons (MNs) from sporadic and familial ALS patients. We find high levels of the RNA-binding proteins NOVA1, NOVA2, and RBFOX2 in the insoluble protein fractions and observe that AS events in ALS-associated MNs are enriched for binding sites of these proteins. Our study points to an early disrupted function of NOVA1 that drives AS changes in a complex fashion, including events caused by a consistent loss of NOVA1 function. NOVA1 exhibits increased cytoplasmic protein levels in early stage MNs without TDP-43 pathology in ALS postmortem tissue. As nuclear TDP-43 protein level depletes, NOVA1 is reduced. Potential indications for a reduction of NOVA1 also came from mice over-expressing TDP-43 lacking its nuclear localization signal and iPSC-MN stressed with puromycin. This study highlights that additional RBP-RNA perturbations in ALS occur in parallel to TDP-43.

• Publisher: Springer Nature B.V
• Subject: Alternative splicing / Amyotrophic lateral sclerosis / Binding sites / Localization / Motor neurons / Pathology / Pluripotency / Proteins / Puromycin / RNA-binding protein / Splicing factors / Stem cells